Anirban Basu, Stergachis Family Endowed Director and Professor of Health Economics, has received the 2025 Health Economics and Outcomes Research (HEOR) Excellence–Application Award from ISPOR – The Professional Society for Health Economics and Outcomes Research.
The award recognizes Basu’s paper, “Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States,” which was developed in collaboration with faculty, students, and postdoctoral researchers at the CHOICE Institute and funded by the National Heart, Lung, and Blood Institute’s Cure Sickle Cell Initiative. The study was published in Annals of Internal Medicine and explores the comparative impact of gene therapy versus standard care for individuals with sickle cell disease in the U.S.
Basu was acknowledged during the ISPOR Awards Ceremony at ISPOR Europe in November 2025.
This award is given to research that demonstrates practical application of health outcomes research and is expected to influence health policy or healthcare decision-making. ISPOR gives preference to work that applies health economics methods to areas such as health technology assessment, policy evaluation, and other topics aligned with the Society’s mission.
Read more about the ISPOR Scientific Achievement and Leadership Awards: https://www.ispor.org/about/awards-grants/scientific-achievement-and-leadership-awards
